Viva Biotech Holdings (HKG:1873)
1.280
-0.050 (-3.76%)
Sep 11, 2026, 4:08 PM HKT
Viva Biotech Holdings Employees
Viva Biotech Holdings had 2,213 employees as of June 30, 2026. The number of employees increased by 44 or 2.03% since the number was reported on December 31, 2025.
Employees
2,213
Change
44
Growth
2.03%
Revenue / Employee
993.32K HKD
Profits / Employee
92.88K HKD
Market Cap
2.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 2,213 | 44 | 2.03% |
| Dec 31, 2025 | 2,169 | 106 | 5.14% |
| Dec 31, 2024 | 2,063 | -14 | -0.67% |
| Dec 31, 2023 | 2,077 | -524 | -20.15% |
| Dec 31, 2022 | 2,601 | 474 | 22.28% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Frontage Holdings | 1,800 |
| AIM Vaccine | 1,466 |
| BioDlink International Company | 594 |
| Jiangsu Recbio Technology | 466 |
| Clover Biopharmaceuticals | 257 |
| Beijing Luzhu Biotechnology | 213 |
| Antengene Corporation | 122 |
| Laekna | 83 |
Viva Biotech Holdings News
- 15 days ago - Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth - PRNewsWire
- 5 months ago - Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up - PRNewsWire
- 5 months ago - Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA - PRNewsWire
- 8 months ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 9 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 11 months ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 1 year ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 1 year ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire